Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Close Brothers to take £165m hit from motor finance scandal

(Sharecast News) - Merchant banking group Close Brothers has revealed that it is to put £165m aside to cover costs associated with the mis-selling of motor finance, following last year's Court of Appeal judgment. The provision, which includes estimates for operational and legal costs, as well as the potential remediation for affected customers, will reduce the company's CET1 capital ratio to 12.0%, down 150 basis points from 13.5% on 31 December. Close Brothers said the hit would be recognised in its second-half results.

However, Close Brothers said that recent actions to improve its capital position will mitigate the impact. These include the sale of its wealth management arm for £200m in September, which is expected to close in the coming weeks and will increase the CET1 capital ratio by around 100 basis points.

Along with "selective loan book growth actions" and "additional cost management initiatives", the CET1 capital ratio should increase back up to around 13% by the end of its financial year (31 July).

"The group's financial strength and ongoing organic capital generation, coupled with the benefits of management actions to build capital, leave us well placed to absorb the impact of the estimated provision," Close Brothers said.

In January 2024, the Financial Conduct Authority launched an investigation into historical motor finance discretionary commission arrangements, after lenders paid commissions to car dealerships without the knowledge of borrowers. A Court of Appeal judgment, which ruled in favour of the claimants in October, has been appealed against by Close Brothers, which is now waiting on a Supreme Court decision.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.